There are 2789 resources available
LBA39 - Personalized combination of neoadjuvant domatinostat, nivolumab (NIVO) and ipilimumab (IPI) in stage IIIB-D melanoma patients (pts) stratified according to the interferon-gamma signature (IFN-γ sign): The DONIMI study
Presenter: Christian Blank
Session: Mini oral session - Melanoma and other skin tumours
Resources:
Abstract
Slides
Webcast
LBA40 - SECOMBIT: The best sequential approach with combo immunotherapy [ipilimumab (I) /nivolumab (N)] and combo target therapy [encorafenib (E)/binimetinib (B)] in patients with BRAF mutated metastatic melanoma: A phase II randomized study
Presenter: Paolo Ascierto
Session: Mini oral session - Melanoma and other skin tumours
Resources:
Abstract
Slides
Webcast
1041MO - 5-year update on COLUMBUS: A randomized phase III trial of encorafenib (enco) + binimetinib (bini) versus enco or vemurafenib (vem) in patients (pts) with BRAF V600-mutant melanoma
Presenter: Reinhard Dummer
Session: Mini oral session - Melanoma and other skin tumours
Resources:
Abstract
Slides
Webcast
LBA67 - Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer who have progressed after prior VEGFR-targeted therapy: Updated results from the phase III COSMIC-311 trial and prespecified subgroup analyses by prior therapy
Presenter: Jaume Capdevila
Session: Mini oral session - NETs and endocrine tumours
Resources:
Abstract
Slides
Webcast
515MO - A phase I trial of durvalumab (Durv) in combination with olaparib (Ola) and capivasertib (Cap) in patients (pts) with advanced or metastatic cancers (Ca) (MEDIPAC)
Presenter: Joline Lim
Session: Mini oral session - Developmental therapeutics
Resources:
Abstract
Slides
Webcast
516MO - Phase I/II study of eprenetapopt (APR-246) in combination with pembrolizumab in patients with solid tumor malignancies
Presenter: Haeseong Park
Session: Mini oral session - Developmental therapeutics
Resources:
Abstract
Slides
Webcast
517MO - Phase I study of the porcupine (PORCN) inhibitor RXC004 in patients with advanced solid tumours
Presenter: Natalie Cook
Session: Mini oral session - Developmental therapeutics
Resources:
Abstract
Slides
Webcast
518MO - Tolerability and preliminary clinical activity of SY-5609, a highly potent and selective oral CDK7 inhibitor, in patients with advanced solid tumors
Presenter: Manish Sharma
Session: Mini oral session - Developmental therapeutics
Resources:
Abstract
Slides
Webcast
519MO - Concordance analysis of treatment recommendations between central consensus and multidisciplinary tumor boards
Presenter: Hidenori Kage
Session: Mini oral session - Developmental therapeutics
Resources:
Abstract
Slides
Webcast
520MO - Using patient-reported outcomes (PROs) in dose-finding oncology trials (DFOT): Results from a global stakeholder survey and the National Cancer Research Institute (NCRI) Consumer Forum
Presenter: Julia Lai-Kwon
Session: Mini oral session - Developmental therapeutics
Resources:
Abstract
Slides
Webcast